What is Impiricus?
Impiricus operates at the intersection of artificial intelligence and healthcare, providing an AI-powered HCP Engagement Engine designed to foster ethical collaborations between medical practitioners and pharmaceutical entities. This engine processes billions of healthcare interactions to deliver real-time communication and actionable insights. The company's solutions are tailored to serve healthcare professionals, including oncologists, gastroenterologists, and dermatologists, aiming to optimize care delivery and improve access to vital resources for underserved physicians. Impiricus collaborates with brand, sales, and medical affairs teams to amplify resource accessibility.
How much funding has Impiricus raised?
Impiricus has raised a total of $3M across 1 funding round:
Angel/Seed
$3M
Angel/Seed (2022): $3M with participation from Surface Ventures and FCA Venture Partners
Key Investors in Impiricus
FCA Venture Partners
FCA Venture Partners is an investment firm focused on transforming healthcare by backing companies that enhance patient care, empower providers, and reduce costs. With over 50 investments and $285 million in capital raised, they have developed expertise in four key sectors: providers, payers, pharma, and innovative care delivery.
Surface Ventures
Surface Ventures is an investment firm that has participated in the recent funding round for Impiricus. Further details on their specific investment focus are not publicly available.
What's next for Impiricus?
The recent major strategic investment positions Impiricus for accelerated growth and market expansion. With a focus on scaling its AI-driven platform, the company is poised to further enhance its capabilities in facilitating critical connections within the healthcare ecosystem. This capital will likely fuel advancements in their HCP Engagement Engine, enabling broader reach and deeper insights into physician needs and pharmaceutical resource utilization. The company's trajectory suggests a continued emphasis on improving patient access to treatments through technological innovation.
See full Impiricus company page
